Closest Analog: Cagrilintide + Semaglutide REDEFINE 1 (Garvey et al., NEJM 2025) is the only Phase 3 trial of an amylin + incretin co-administered combination in adults without diabetes
It doesnt spike cortisol or prolactin, doesnt induce massive hunger, and avoids the desensitization issues seen with older GH secretagogues
GLP-1, GLP-2, And Peptide Syringe Questions GLP-1, GLP-2, and peptide syringe needs depend first on the medication format
In the obese trial cohort, 1 mg moved 24-hour heart rate by +0.7 bpm in the first week, essentially placebo. In a healthy lean Phase 1b group, the same dose raised heart rate by about 10 bpm, with a peak near 15 to 20 bpm around days 4 to 6. Lean, younger participants had more reactive heart-rate control than the sedentary, obese, and metabolically stressed trial population
Side Effects Gastrointestinal symptoms: Most common adverse effects were mild-to-moderate nausea, vomiting, and diarrhea, occurring primarily during dose escalation [6] [12]
